Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, Hui, Zhang, Yuntao, Huang, Baoying, Deng, Wei, Quan, Yaru, Wang, Wenling, Xu, Wenbo, Zhao, Yuxiu +24 more·2020·Cell
DOI 10.1016/j.cell.2020.06.008

Cited by (749)

Items 201–300 of 749

  1. SARS-CoV-2 vaccine candidates in rapid development
    Li-Feng Li, Pengbo Guo, Xiaoman Zhang, Zhi-Dan Yu, Wan-Cun Zhang, Hui-Qing Sun · 2020 · Human Vaccines & Immunotherapeutics
  2. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
    Ze-Jun Wang, Huajun Zhang, Jia Lu, Kang-Wei Xu, Cheng Peng, Jing Hui Guo, Xiao-Xiao Gao, Xin Hua Wan, Wen-Hui Wang, Chao Shan et al. · 2020 · Emerging Microbes & Infections
  3. Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments
    Sareh Pandamooz, Benjamin Jurek, Carl-Philipp Meinung, Zahra Baharvand, Alireza Sahebi Shahem-abadi, Silke Haerteis, Jaleel A. Miyan, James R. Downing, Mehdi Dianatpour, Afshin Borhani‐Haghighi et al. · 2021 · The Annual Review of Pharmacology and Toxicology
  4. Effectiveness of COVID‑19 vaccines and their challenges (Review)
    Gabriella Marfè, Stefania Perna, Arvind Kumar Shukla · 2021 · Experimental and Therapeutic Medicine
  5. A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations
    Lidan Hu, Jingmiao Sun, Yan Wang, Danny Junyi Tan, Zhongkai Cao, Langping Gao, Yuelin Guan, Xiuwei Jia, Jianhua Mao · 2023 · Vaccines
  6. SARS‐CoV‐2: Mechanism of infection and emerging technologies for future prospects
    Shiqin Li, Sijia Li, Cyrollah Disoma, Rong Zheng, Mei Ling Zhou, Aroona Razzaq, Pinjia Liu, Yuzheng Zhou, Zijun Dong, Ashuai Du et al. · 2020 · Reviews in Medical Virology
  7. Current progress and challenges in the design and development of a successful COVID-19 vaccine
    Tingting Li, Tianying Zhang, Ying Gu, Shaowei Li, Ningshao Xia · 2021 · Fundamental Research
  8. Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
    Kevin R. Bewley, Karen E. Gooch, Kelly M. Thomas, Stéphanie Longet, Nathan R. Wiblin, Laura E. Hunter, Kin Chan, Phillip J. Brown, Rebecca A Russell, Catherine M. K. Ho et al. · 2021 · Science Advances
  9. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
    Yanghong Ni, Aqu Alu, Lei Hong, Yang Wang, Min Wu, Xiawei Wei · 2021 · Molecular Biomedicine
  10. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
    Shihao Zhou, Yuting Li, Ruyan Zhang · 2022 · Frontiers in Immunology
  11. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
    Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, Narasimha Reddy Molugu, Sai D. Prasad, Srinivas Vellimudu, Krishna M. Ella, Rajaram Ravikrishnan, Amit Awasthi, Jomy Jose et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  12. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
    Rashed Noor, Saadia Shareen, Muntasir Billah · 2022 · Bulletin of the National Research Centre/Bulletin of the National Research Center
  13. Severe acute respiratory syndrome coronavirus‐2 natural animal reservoirs and experimental models: systematic review
    Salma N. Younes, N. Younes, F. Shurrab, Gheyath K Nasrallah · 2020 · Reviews in Medical Virology
  14. The role and uses of antibodies in COVID-19 infections: a living review
    David Oliver Scourfield, Sophie G. Reed, Max N. Quastel, Jennifer Alderson, Valentina M T Bart, Alicia Teijeira Crespo, Ruth E. Jones, Ellie Pring, Felix Clemens Richter, David Ahern et al. · 2021 · Oxford Open Immunology
  15. COVID-19 Research: Lessons from Non-Human Primate Models
    Laure Albrecht, Elodie Bishop, Basile Jay, Blaise Lafoux, Marie Minoves, Caroline Passaes · 2021 · Vaccines
  16. The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
    Zhongjie Sun, Tingxin Wu, Huangfan Xie, Yuhuan Li, Jinlan Zhang, Xun‐Cheng Su, Hailong Qi · 2022 · Vaccines
  17. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders
    Charlene Yat Che Chau, Loraine L. W. Chow, Siddharth Sridhar, Kendrick Co Shih · 2021 · Ophthalmology and Therapy
  18. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks
    Miao Cao, Xiaojie Su, Shibo Jiang · 2021 · Stem Cell Reports
  19. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
    Rianna Vandergaast, Timothy S. Carey, Samantha Reiter, Chase Lathrum, Patrycja J. Lech, Clement W. Gnanadurai, Michelle Haselton, Jason Buehler, Riya Narjari, Luke Schnebeck et al. · 2021 · mSphere
  20. The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination
    Ger T. Rijkers, Frans J. van Overveld · 2021 · Clinical Immunology Communications
  21. COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
    Hadeel T. Al-Jighefee, Hoda Najjar, Muna Nizar Ahmed, Abeer Qush, Sara Awwad, Layla Kamareddine · 2021 · Vaccines
  22. How to Understand Herd Immunity in the Context of COVID-19
    Ming‐Hao Dong, Feng He, Yu Deng · 2020 · Viral Immunology
  23. A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19
    Sayed F. Abdelwahab, Usama Hamed Issa, Hossam M. Ashour · 2021 · Vaccines
  24. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor
    Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Rui Costa, Nandini Venkatesan, Xiangliang Lin, Long V. Pham, Shan Feng, Ulrik Fahnøe, Troels K. H. Scheel et al. · 2021 · Vaccines
  25. Overview of Nonhuman Primate Models of SARS-CoV-2.
    A. Trichel · 2021 · Comparative medicine
  26. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
    Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, Suvichada Assawakosri, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakana Wongsrisang, Donchida Srimuan, Thaksaporn Thatsanatorn et al. · 2022 · Vaccines
  27. Analysis of SARS-CoV-2 viral loads in stool samples and nasopharyngeal swabs from COVID-19 patients in the United Arab Emirates
    Mariane Daou, Hussein Kannout, Mariam Khalili, Mohamed Almarei, Mohamed Alhashami, Zainab Alhalwachi, Fatima Yousif Alshamsi, Mohammad Tahseen Al Bataineh, Mohd Azzam Kayasseh, Abdulmajeed S. AlKhajeh et al. · 2022 · PLoS ONE
  28. Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus
    Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Yogendra Shantaram Padwad, Vipin K. Hallan, Sanjay Kumar · 2022 · Pharmacological Reports
  29. From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
    Gang-Gang Miao, Zhi-Qiang Chen, Heng-Song Cao, Wenhao Wu, Xing-Lin Chu, Han-Yuan Liu, Leyao Zhang, Hongfei Zhu, Hong-Zhou Cai, Xiaolan Lu et al. · 2023 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  30. Virus Irradiation and COVID-19 Disease
    Marco Durante, Kai Schulze, S. Incerti · 2020 · Frontiers in Physics
  31. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response
    Qiudong Su, Yening Zou, Yi Yao et al. · 2021 · Vaccine
  32. Development of COVID-19 vaccines utilizing gene therapy technology
    Hironori Nakagami · 2021 · International Immunology
  33. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
    Shengxue Luo, Panli Zhang, Bochao Liu, Chan Yang, Chaolan Liang, Qi Ming Wang, Ling Zhang, Xi Tang, Jinfeng Li, Shuiping Hou et al. · 2021 · Emerging Microbes & Infections
  34. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19
    Kun Xu, Yaling An, Qunlong Li, Wei-Jing Huang, Yuxuan Han, Tianyi Zheng, Fang Fang, Hui Liu, Chuan-Yu Liu, Ping Gao et al. · 2021 · Emerging Microbes and Infections
  35. Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
    Ramesh J. L. Kandimalla, Pratik Chakraborty, Jayalakshmi Vallamkondu, Anupama Chaudhary, Sonalinandini Samanta, P. Hemachandra Reddy, Vincenzo De Feo, Saikat Dewanjee · 2021 · Biomedicines
  36. Plant-Based Vaccines in Combat against Coronavirus Diseases
    Benita Ortega-Berlanga, Tomasz Pniewski · 2022 · Vaccines
  37. Various vaccine platforms in the field of COVID-19
    Kus Fiani Savina, Rakhy Sreekumar, V K Soonu, E. Jayadevi Variyar · 2022 · Beni-Suef University Journal of Basic and Applied Sciences
  38. Advances in Vaccine Development of the Emerging Novel Genotype Fowl Adenovirus 4
    Aijing Liu, Yu Zhang, Hongyu Cui · 2022 · Frontiers in Immunology
  39. Protective cellular and humoral immune responses to Edwardsiella tarda in flounder (Paralichthys olivaceus) immunized by an inactivated vaccine
    Xiaoyan Wu, Jing Xing, Xiaoqian Tang · 2022 · Molecular Immunology
  40. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
    Gelareh Abdolmaleki, Mina Azam Taheri, Sarina Paridehpour, Neshaut Mashreghi Mohammadi, Yasaman Ahmadi Tabatabaei, Taraneh Mousavi, Mohsen Amin · 2022 · DARU Journal of Pharmaceutical Sciences
  41. PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals
    Amitis Ramezani, Rahim Sorouri, Saiedeh Haji‐Maghsoudi, Sarah Dahmardeh, Delaram Doroud, Mona Sadat Larijani, Sana Eybpoosh, Ehsan Mostafavi, Alireza Olyaeemanesh, ‪Mostafa Salehi-Vaziri et al. · 2023 · Scientific Reports
  42. Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
    Yuki Furuse, Hitoshi Oshitani · 2020 · Frontiers in Microbiology
  43. A promising inactivated whole-virion SARS-CoV-2 vaccine
    Исакова-Сивак Ирина Николаевна, Руденко Лариса Георгиевна · 2020 · The Lancet Infectious Diseases
  44. A safety consideration of mesenchymal stem cell therapy on COVID-19
    Yajun Cao, Hongyan Wu, Wanli Zhai, Ying Wang, Mengdi Li, Meng Li, Liu Yang, Ye Tian, Yunhao Song, Jun Li et al. · 2020 · Stem Cell Research
  45. Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future
    Ester Calvo Fernández, Lucie Y. Zhu · 2020 · British Journal of Clinical Pharmacology
  46. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome‐Corona Virus‐2 (SARS‐CoV‐2)
    Narasimha Murthy Beeraka, SubbaRao V. Tulimilli, Medha Karnik, Surya Prabha Sadhu, Rajeswara Rao Pragada, Gjumrakch Aliev, SubbaRao V. Madhunapantula · 2021 · BioMed Research International
  47. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates
    Limin Yang, Deyu Tian, Jian-Bao Han, Wenhui Fan, Yuan Zhang, Yunlong Li, Wenqiang Sun, Yanqiu Wei, Xiaodong Tian, Dan-Dan Yu et al. · 2021 · The Innovation
  48. Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
    Lin Cheng, Shuo Song, Qing Fan, Senlin Shen, Haiyan Wang, Bing Zhou, Xiangyang Ge, Bin Ju, Zheng Zhang · 2021 · Cell Discovery
  49. COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
    Marek Jutel, Marı́a José Torres, Óscar Palomares, Cezmi A. Akdiş, Thomas Eiwegger, Eva Untersmayr, Domingo Barber, Magdalena Zemelka‐Wiącek, Anna Kosowska, Elizabeth N. Palmer et al. · 2022 · Allergy
  50. Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
    Ramireddy Bommireddy, Shannon Stone, Noopur Bhatnagar, Pratima Kumari, Luis E. Muñoz, Judy Oh, Ki‐Hye Kim, Jameson T. L. Berry, Kristen M. Jacobsen, Lahcen Jaafar et al. · 2022 · Vaccines
  51. Vaccines against SARS-CoV-2 variants and future pandemics
    Taeyoung Park, Hyogyeong Hwang, Suhyeong Moon, Sang Gu Kang, Seunghyup Song, Young Hun Kim, Hanbi Kim, Eun‐Ju Ko, Soon‐Do Yoon, Sang‐Moo Kang et al. · 2022 · Expert Review of Vaccines
  52. Attitudes toward Receiving COVID-19 Booster Dose in the Middle East and North Africa (MENA) Region: A Cross-Sectional Study of 3041 Fully Vaccinated Participants
    Mohamed Abouzid, Alhassan Ali Ahmed, Dina M. El‐Sherif, Wadi B. Alonazi, Ahmed Ismail Eatmann, Mohammed M. Alshehri, Raghad Saleh, Mareb H. Ahmed, Ibrahim Adel Aziz, Asmaa E. Abdelslam et al. · 2022 · Vaccines
  53. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
    Jie Zhou, Zezhong Liu, Guangxu Zhang, Wei Xu, Lixiao Xing, Lu Lu, Qian Wang, Shibo Jiang · 2022 · Journal of Medical Virology
  54. A comprehensive review on variants of SARS-CoVs-2: Challenges, solutions and open issues
    Deepanshi Deepanshi, Ishan Budhiraja, Deepak Garg, Neeraj Kumar, Rohit Sharma · 2022 · Computer Communications
  55. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
    M. Joyce, Hannah A. D. King, Ines Elakhal Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, C. Subra, Rita E. Chen, P. Thomas, Wei-Hung Chen et al. · 2021 · bioRxiv
  56. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
    Martin Sebastian Winkler, Tomasz Skirecki, Frank Martin Brunkhorst, Sara Cajander, Jean‐Marc Cavaillon, Ricard Ferrer, Stefanie B. Flohé, Alberto García‐Salido, Evangelos J. Giamarellos‐Bourboulis, Massimo Girardis et al. · 2021 · EBioMedicine
  57. State of assisted reproduction technology in the coronavirus disease 2019 era and consequences on human reproductive system
    Anadeep Chandi, Neelam Jain · 2021 · Biology of Reproduction
  58. SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
    Lunzhi Yuan, Qiyi Tang, Huachen Zhu, Yi Guan, Tong Cheng, Ningshao Xia · 2021 · Emerging Microbes & Infections
  59. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
    Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Mengze Gan, Xiaosong Lin, Xionglin Fan · 2021 · Frontiers in Immunology
  60. Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
    Chaonan Li, Yikai Guo, Zhongbiao Fang, Haiyan Zhang, Yanjun Zhang, Keda Chen · 2022 · Frontiers in Immunology
  61. Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light
    A. Gracheva, E. Korchevaya, Yulia Ammour, D. Smirnova, O. Sokolova, G. Glukhov, A. Moiseenko, I. V. Zubarev, R. Samoilikov, I. Leneva et al. · 2022 · Archives of Virology
  62. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
    Nicolás Gonzalo Núñez, Jonas Schmid, Laura Power, Chiara Alberti, Sinduya Krishnarajah, Stefanie Kreutmair, Susanne Unger, Sebastián Blanco, Brenda Salomé Konigheim, Constanza Marín et al. · 2023 · Nature Immunology
  63. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward
    Vipin M. Vashishtha, Puneet Kumar · 2020 · Human Vaccines & Immunotherapeutics
  64. Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates
    Yan-Feng Yao, Ze-Jun Wang, Ren-Di Jiang, Xue Hu, Huajun Zhang, Yi-Wu Zhou, Ge Gao, Ying Chen, Yun Peng, Mei-Qin Liu et al. · 2021 · Virologica Sinica
  65. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
    Jiajing Wu, Li Zhang, Yue Zhang, Haixin Wang, Ruxia Ding, Jianhui Nie, Qianqian Li, Shuo Liu, Yongxin Yu, Xiaoming Yang et al. · 2021 · Frontiers in Immunology
  66. A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?
    Rashed Noor · 2021 · Current Clinical Microbiology Reports
  67. Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
    Rezvan Hosseinzadeh, Mohammad Barary, Hamed Mehdinezhad, Terence Tai Weng Sio, Florian Peter Länger, Sahar Khosravi · 2022 · Research and Practice in Thrombosis and Haemostasis
  68. An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines
    S. Al-Sheboul, Brent Brown, Yasemin Shboul, Ingo Fricke, Chinua Imarogbe, K. Alzoubi · 2022 · Vaccines
  69. A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants
    Xuefan Wu, Wei Li, Heng Rong, Jingdi Pan, Xiaowei Zhang, Qinxue Hu, Zheng‐Li Shi, Xian‐En Zhang, Zongqiang Cui · 2024 · ACS Nano
  70. Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19
    Bader M. Jarai, Zachary S. Stillman, Kartik Bomb, April M. Kloxin, Catherine A. Fromen · 2020 · ACS Biomaterials Science & Engineering
  71. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
    T. Lambe, Alexandra J. Spencer, Kelly M. Thomas, K. Gooch, Stephen R. Thomas, A. White, H. Humphries, Daniel Wright, Sandra Belij-Rammerstorfer, Nazia Thakur et al. · 2021 · Communications Biology
  72. A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
    Sylvie Roy, Karim Ghani, Pedro Otavio de Campos-Lima, Manuel Caruso · 2021 · Virus Research
  73. Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine
    Guangli Hu, Xin Luo, Jiamin Liao, Chuangchao Zou, Yihui Huang, Rui Geng, Zhiqing Zhao, Hanqin Shen, Yongchang Cao, Ouyang Peng et al. · 2025 · Veterinary Quarterly
  74. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development
    Iqra Mehmood, Munazza Ijaz, Sajjad Ahmad, Temoor Ahmed, Amna Bari, Asma Abro, Khaled S. Allemailem, Ahmad Almatroudi, Muhammad Tahir ul Qamar · 2021 · International Journal of Environmental Research and Public Health
  75. The importance of genomic analysis in cracking the coronavirus pandemic
    Davide Zella, Marta Giovanetti, Eleonora Cella, Alessândra Borsetti, Marco Ciotti, Giancarlo Ceccarelli, Gabriella d’Ettorre, Aldo Pezzuto, Vittoradolfo Tambone, Laura Leondina Campanozzi et al. · 2021 · Expert Review of Molecular Diagnostics
  76. Influenza Virus and SARS-CoV-2 Vaccines
    Adam Sandor, Michael S. Sturdivant, Jenny P.‐Y. Ting · 2021 · The Journal of Immunology
  77. Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
    Carlos Alberto Labarrere, Ghassan S. Kassab · 2021 · Frontiers in Immunology
  78. Development of Inactivated FAKHRAVAC® Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models
    Soheil Ghasemi, Kosar Naderi Saffar, Firooz Ebrahimi, Pezhman Khatami, Arina Monazah, Ghorban-Ali Alizadeh, Hossein-Ali Ettehadi, Iman Rad, Shahrzad Nojehdehi, Mousa Kehtari et al. · 2021 · Vaccines
  79. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma
    J. Deere, Timothy D. Carroll, Joseph C. Dutra, L. Fritts, R. Sammak, J. Yee, K. Olstad, J. Reader, A. Kistler, J. Kamm et al. · 2021 · Microbiology spectrum
  80. Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
    Huibi Cao, Juntao Mai, Zhichang Peter Zhou, Zhijie Li, Rongqi Cathleen Duan, Jacqueline Watt, Ziyan Chen, Ranmal Avinash Bandara, Ming Li, Sang Kyun Ahn et al. · 2021 · Cell & Bioscience
  81. Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects
    Yuri A. Lazebnik · 2021 · Oncotarget
  82. Application of Traditional Vaccine Development Strategies to SARS-CoV-2
    Halie M. Rando, Ronan Lordan, Alexandra J. Lee, Amruta S. Naik, Nils Wellhausen, Elizabeth Sell, Likhitha Kolla, Anthony Gitter, Casey S. Greene, Vikas Bansal et al. · 2023 · mSystems
  83. Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity
    Weitong Yao, Danting Ma, Haimin Wang, Xiaojuan Tang, Chengzhi Du, Hong Pan, Chao Li, Hua Lin, Michael Farzan, Jincun Zhao et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  84. SARS-CoV-2 spike conformation determines plasma neutralizing activity
    John E. Bowen, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Cameron Stewart, M. Alejandra Tortorici, Nicholas Franko, Jennifer K. Logue, Ignacio G. Mazzitelli, Sasha W. Tilles et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
    Li, Xiaoman, Pan, Yongbing, Yin, Qiangling, Wang, Zejun, Shan, Sisi, Zhang, Laixing, Yu, Jinfang, Qu, Yuanyuan, Sun, Lina, Gui, Fang et al. · 2022 · Cell Discovery
  86. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
    Isaac Kyei-Barffour, Samuel Akwetey Addo, E. Aninagyei, George Ghartey-Kwansah, D. O. Acheampong · 2021 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  87. Advances of nanomaterials‐based strategies for fighting against COVID‐19
    Chunxi Zeng, Xucheng Hou, Margaret Bohmer, Yizhou Dong · 2021 · Open Research (University of Surrey)
  88. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
    Ali Salimi Jeda, Sina Abbassi, Atieh Mousavizadeh, Maryam Esghaie, Farah Bokharaei‐Salim, Farhad Jeddi, Maryam Shafaati, Asghar Abdoli · 2021 · International Immunopharmacology
  89. Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast
    A. Inchingolo, G. Malcangi, Sabino Ceci, A. Patano, Alberto Corriero, L. Vimercati, Daniela Azzollini, G. Marinelli, G. Coloccia, Fabio Piras et al. · 2022 · International Journal of Molecular Sciences
  90. Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review.
    Omid Dadras, Esmaeil Mehraeen, Amirali Karimi, Marcarious Moorkereh Tantuoyir, Arian Afzalian, Newsha Nazarian, Hengameh Mojdeganlou, Pegah Mirzapour, Ahmadreza Shamsabadi, Mohsen Dashti et al. · 2022 · Archives of Academic Emergency Medicine
  91. Long-Term Antibody Response to SARS-CoV-2 in Children
    Gábor Artúr Dunay, Madalena Barroso, Mathias Woidy, Marta K. Danecka, Géraldine Engels, Katharina Hermann, Friederike S. Neumann, Kevin Paul, Jan Beime, Gabriele Escherich et al. · 2022 · Journal of Clinical Immunology
  92. Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine
    Jianhua Yin, Yingze Zhao, Fubaoqian Huang, Yunkai Yang, Yaling Huang, Zhenkun Zhuang, Yanxia Wang, Zhifeng Wang, Xiumei Lin, Yuhui Zheng et al. · 2022 · The Innovation
  93. An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines
    Han Cao, Shengran Yang, Yunfei Wang · 2021 · Vaccines
  94. Efforts towards a COVID ‐19 vaccine
    Harald Brüssow · 2020 · Environmental Microbiology
  95. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
    Yi-Sheng Sun, Jingjing Zhou, Han-Ping Zhu, Fang Xu, Wen-Bin Zhao, Hangjing Lu, Zhen Wang, Shu-Qing Chen, Ping-Ping Yao, Jianmin Jiang et al. · 2021 · Viruses
  96. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
    Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, Eliana F. Castro, Laura A. Bruno, William B. Stone, Paula S. Pérez, M. Laura Darriba, Lucia Beatriz Chemes, Julieta Alcaín et al. · 2022 · Frontiers in Immunology
  97. Rational Development of a Polysaccharide–Protein‐Conjugated Nanoparticle Vaccine Against SARS‐CoV‐2 Variants and Streptococcus pneumoniae
    Yong‐Qiang Deng, Jing Li, Chunyun Sun, Hang Chi, Dan Luo, Rui Wang, Hongying Qiu, Yanjing Zhang, Mei Li Wu, Xiao Zhang et al. · 2022 · Advanced Materials
  98. A Review of Different Vaccines and Strategies to Combat COVID-19
    S. Sabitha, Nagarajan Shobana, Pandurangan Prakash, Sathiyamoorthy Padmanaban, Mahendran Sathiyasree, Subramanian Saigeetha, Srikumar Chakravarthi, Saji Uthaman, In‐Kyu Park, Antony Vincent Samrot · 2022 · Vaccines
  99. SARS-CoV-2 herd immunity of the Kyrgyz population in 2021
    Anna Yurievna Popova, OMOR TILEGENOVICH KASYMOV, Vyacheslav Y. Smolenski, В. С. Смирнов, Svetlana Alexandrovna Egorova, Zuridin Sharipovich Nurmatov, Angelica Marsovna Milichkina, Gulmira Saibildaevna Suranbaeva, Tatyana Enverovna Kuchuk, I. V. Khamitova et al. · 2022 · Medical Microbiology and Immunology
  100. Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20
    Mingtao Liu, Hui Gan, Yilu Lin, Runpei Lin, Mingshan Xue, Teng Zhang, Zhangkai Jason Cheng, Baoqing Sun · 2022 · International Journal of Environmental Research and Public Health